S. Allan

发表

A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.

R. Agarwal, U. Banerji, J. Spicer, 2012 .

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma

C. Winter, H. Do, A. Dobrovic, 2019, Scientific Reports.

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Andrew W Boyd, Martin Lackmann, Angus Harding, 2013, Cancer cell.

ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.

A. Boyd, Jacinta C. Carter, M. Spanevello, 2011, Neuro-oncology.

Neoadjuvant and adjuvant treatment of renal cell carcinoma

T. Powles, S. Rudman, S. Chowdhury, 2012, Expert review of anticancer therapy.

Neoadjuvant and adjuvant treatment of renal cell

T. Powles, S. Rudman, S. Chowdhury, 2012 .

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy

R. Spreafico, F. Farzaneh, P. Ross, 2014, British Journal of Cancer.

Glioma Surgical Aspirate: A Viable Source of Tumor Tissue for Experimental Research

C. Winter, A. Boyd, G. Osborne, 2013, Cancers.

Publisher Correction: A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma

C. Winter, H. Do, A. Boyd, 2020, Scientific Reports.

P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer

L. Paz-Ares, W. Edenfield, F. Braiteh, 2019, International Journal of Gynecological Cancer.